Saturday, January 12, 2019 1:49:02 PM
This is why Bayer would want to buy RDGL:
Bayer even bought a company to help in their mission to kill tumors and the new new company still can't do it without damaging the surrounding tissue. The are shooting for an acceptable amount of damage!
By trying to find just the right strength that will kill a tumor without causing damage to the surrounding tissue. But they are on the wrong track because different tumors need different strengths of radiation to kill them. Plus what is acceptable damage?
I would say only Zero damage is acceptable.
Maybe they should buy RDGL. Here is your proof:
explains Dr. Alan Cuthbertson, Head of Thorium Research at Bayer in Oslo, Norway. He and his team were part of Algeta ASA, a company that was acquired by Bayer in 2013. These specialists in the use of alpha particle-emittting radionuclides in radiotherapy are working on a means of transporting thorium directly to the tumor where the radioisotope first accumulates and then decays, releasing the alpha particles. “The radiation then destroys cancer cells without damaging the surrounding healthy tissue too severely,” explains the Bayer chemist.
https://www.research.bayer.com/en/fighting-cancer-with-radio-immunotherapy.aspx
Bayer even bought a company to help in their mission to kill tumors and the new new company still can't do it without damaging the surrounding tissue. The are shooting for an acceptable amount of damage!
By trying to find just the right strength that will kill a tumor without causing damage to the surrounding tissue. But they are on the wrong track because different tumors need different strengths of radiation to kill them. Plus what is acceptable damage?
I would say only Zero damage is acceptable.
Maybe they should buy RDGL. Here is your proof:
explains Dr. Alan Cuthbertson, Head of Thorium Research at Bayer in Oslo, Norway. He and his team were part of Algeta ASA, a company that was acquired by Bayer in 2013. These specialists in the use of alpha particle-emittting radionuclides in radiotherapy are working on a means of transporting thorium directly to the tumor where the radioisotope first accumulates and then decays, releasing the alpha particles. “The radiation then destroys cancer cells without damaging the surrounding healthy tissue too severely,” explains the Bayer chemist.
https://www.research.bayer.com/en/fighting-cancer-with-radio-immunotherapy.aspx
Recent RDGL News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:44:48 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 03/06/2026 05:15:04 AM
- Form 1-A/A - Offering Statement [Regulation A]: [Amend] • Edgar (US Regulatory) • 03/04/2026 04:48:52 PM
- Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites • GlobeNewswire Inc. • 02/17/2026 01:30:00 PM
- Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™ • GlobeNewswire Inc. • 02/10/2026 01:30:00 PM
- Vivos Inc Updates Human Therapy Progress in India • GlobeNewswire Inc. • 02/03/2026 01:30:00 PM
- Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals • GlobeNewswire Inc. • 01/28/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2026 04:06:21 PM
- Vivos Inc Summarizes Progress in its Animal Therapy Division • GlobeNewswire Inc. • 12/22/2025 05:56:08 PM
- Vivos Inc Summarzes Preogress in its Animal Therapy Division • GlobeNewswire Inc. • 12/22/2025 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/09/2025 09:00:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2025 12:34:42 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 11:08:03 AM
- Vivos Inc. Issues Shareholder Update Letter • GlobeNewswire Inc. • 11/06/2025 01:30:00 PM
- Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics • GlobeNewswire Inc. • 10/29/2025 12:30:00 PM
- Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel® • GlobeNewswire Inc. • 10/27/2025 12:30:00 PM
- Vivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity in India • GlobeNewswire Inc. • 09/29/2025 05:46:00 PM
- Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India • GlobeNewswire Inc. • 09/29/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:01:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 07:32:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2025 09:14:29 PM
